FDA to approve ibogaine for human trials

The U.S. Food and Drug Administration (FDA) is set to approve an investigational new drug clearance for ibogaine, a psychoactive substance derived from plants. This approval will pave the way for the first ever human trials of the drug in the United States. The move represents a significant regulatory shift for a substance that has been studied for potential therapeutic uses, including addiction treatment. The clearance is a critical step required before clinical research on human subjects can begin.